After a comprehensive executive search that was filled in less than two months, The Chase Group is pleased to announce the placement of Carla Poulson… Continue Reading →
Akcea Therapeutics is focused on helping patients living with rare diseases by understanding patient and physician needs by bringing transformative medicines to market. Akcea is… Continue Reading →
The Chase Group is proud to partner with Eisai and support their human health care mission by securing a strong and agile leader for their… Continue Reading →
Akcea Therapeutics is driven by determination and focus on addressing the unmet needs and complex medical challenges of patients with serious and rare disorders. As… Continue Reading →
At the crossroads of innovation and advanced technology, Alexza Pharmaceuticals is working to develop products for the acute treatment of underserved medical needs in neuroscience…. Continue Reading →
To support their rapid growth and expanding portfolio of rare disease programs, Aeglea Biotherapeutics retained The Chase Group and successfully secured a new Global Program… Continue Reading →
Eisai, Inc.’s partnership with Merck has proven to be successful with the FDA approval of the Keytruda and Lenvima Combination Treatment. With 13 indications for… Continue Reading →
The Chase Group is excited to reengage partnership with Akcea Therapeutics to recruit the company’s Vice President of Human Resources. The Vice President will lead… Continue Reading →
As the leading innovator in RNA-targeted therapeutics, Ionis Pharmaceuticals requires world-class scientists and business leaders whose passion to innovate is matched only by their commitment… Continue Reading →
A boutique firm working exclusively in life sciences, The Chase Group, with 25+ years’ executive search experience, can identify and deliver the highest quality executives… Continue Reading →